Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
DM O'Malley, A Oaknin, BJ Monk, F Selle, C Rojas… - Gynecologic …, 2021 - Elsevier
Objective This phase II clinical trial evaluated the safety and antitumor activity of balstilimab,
an anti-PD-1 antibody, in patients with previously-treated, recurrent/metastatic cervical …
an anti-PD-1 antibody, in patients with previously-treated, recurrent/metastatic cervical …
Monoclonal antibodies in cervical malignancy-related HPV
Despite many efforts to treat HPV infection, cervical cancer survival is still poor for several
reasons, including resistance to chemotherapy and relapse. Numerous treatments such as …
reasons, including resistance to chemotherapy and relapse. Numerous treatments such as …
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer
DM O'Malley, LM Randall, CG Jackson… - Future …, 2021 - Taylor & Francis
Balstilimab (anti-programmed death 1) and zalifrelimab (anti-CTLA-4) are two new
checkpoint inhibitors that have emerged as promising investigational agents for the …
checkpoint inhibitors that have emerged as promising investigational agents for the …
[HTML][HTML] The role of immunotherapy in the treatment of advanced cervical cancer: current status and future perspectives
Cervical cancer remains one of the most common cancers in women around the world
however therapeutic options in the advanced and recurrent setting are limited. Immune …
however therapeutic options in the advanced and recurrent setting are limited. Immune …
Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer
CK Bose - Medical Oncology, 2022 - Springer
Recurrent and metastatic cervical cancer is generally treated by cisplatin, paclitaxel, and
bevacizumab with limited benefit this constituting an unmet need. Immune checkpoint …
bevacizumab with limited benefit this constituting an unmet need. Immune checkpoint …
Anti-PD-1 antibodies and methods of use thereof
M Van Dijk, NS Wilson, CA Mundt, G Ritter… - US Patent …, 2019 - Google Patents
2016-10-13 Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER reassignment
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …
Systemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival
E Paulino, AC de Melo, DAP de Andrade… - Critical Reviews in …, 2023 - Elsevier
Cervical cancer (CC) is a worldwide problem, especially in low-and middle-income
countries, where patients are often diagnosed with locally advanced disease. Until recently …
countries, where patients are often diagnosed with locally advanced disease. Until recently …
Anti-PD-1 antibodies and methods of use thereof
M Van Dijk, CA Mundt, G Ritter, JD Wolchok… - US Patent …, 2022 - Google Patents
2021-03-30 Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER reassignment
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …
Antibodies and methods of use thereof
M Van Dijk, CA Mundt, G Ritter, D Schaer… - US Patent …, 2024 - Google Patents
Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-
4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising …
4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising …
Anti-PD-1 antibodies and methods of use thereof
M Van Dijk, CA Mundt, G Ritter, JD Wolchok… - US Patent …, 2019 - Google Patents
2019-06-27 Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER reassignment
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …
MEMORIAL SLOAN KETTERING CANCER CENTER ASSIGNMENT OF ASSIGNORS …